US2014100256A1PendingUtilityA1

Formulations of enzalutamide

59
Assignee: BEND RESPriority: Sep 11, 2012Filed: Sep 11, 2013Published: Apr 10, 2014
Est. expirySep 11, 2032(~6.1 yrs left)· nominal 20-yr term from priority
Inventors:Douglas Alan LorenzSanjay KonagurthuRandy J. WaldJason A. EverettSheila MatzYuuki TakaishiToshiro SakaiRyousuke IrieShinsuke ObaHiroyasu ToyotaKoji NishimuraAtsushi Kanbayashi
A61P 43/00A61P 35/00A61K 9/1652A61P 13/08A61P 15/00A61P 15/08A61P 15/14C07D 233/86A61K 31/4164A61K 47/32A61K 9/2054A61K 31/4166A61K 47/38A61K 9/16A61K 9/10A61K 9/2095A61K 9/146A61K 9/2027A61K 9/1635
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition comprising a solid dispersion containing enzalutamide and a polymer, wherein the polymer is 0.5 to 7 parts by weight, with respect to 1 part by weight of the enzalutamide. 
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein enzalutamide is an amorphous state. 
     
     
         3 . The pharmaceutical composition according to  claim 1 , wherein the polymer is a polymer or two or more polymers selected from the group consisting of polyvinyl pyrrolidone, polyethyleneoxide, poly(vinyl pyrrolidone-co-vinyl acetate), polymethacrylates, polyoxyethylene alkyl ethers, polyoxyethylene castor oils, polycaprolactam, polylactic acid, polyglycolic acid, poly(lactic-glycolic) acid, lipids, cellulose, pullulan, dextran, maltodextrin, hyaluronic acid, polysialic acid, chondroitin sulfate, heparin, fucoidan, pentosan polysulfate, spirulan, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxymethyl ethylcellulose, hydroxypropyl methylcellulose acetate succinate, cellulose acetate phthalate, cellulose acetate trimellitate, ethyl cellulose, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, and dextran polymer derivative. 
     
     
         4 . The pharmaceutical composition according to  claim 3 , wherein the polymer is hydroxypropyl methylcellulose acetate succinate.

Join the waitlist — get patent alerts

Track US2014100256A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.